Lasmiditan

Lasmiditan
Clinical data
Pronunciation	/læzˈmɪdɪtæn/; laz-MID-i-tan
Trade names	Reyvow, Rayvow
Other names	COL-144; COL144; LY-573144; LY573144
AHFS/Drugs.com	Monograph
MedlinePlus	a620015
License data	US DailyMed: Lasmiditan;
Routes of; administration	By mouth, intravenous
Drug class	Serotonin 5-HT1F receptor agonist; Antimigraine agent
ATC code	N02CC08 (WHO) ;
Legal status
Legal status	US: Schedule V; EU: Rx-only;
Identifiers
	IUPAC name 2,4,6-Trifluoro-N-[6-[(1-methyl-4-piperidinyl)carbonyl]-2-pyridinyl]benzamide;
CAS Number	439239-90-4 ;
PubChem CID	11610526;
IUPHAR/BPS	3928;
DrugBank	DB11732 ;
ChemSpider	9785281 ;
UNII	760I9WM792;
KEGG	D10338 ;
CompTox Dashboard (EPA)	DTXSID40469435 ;
Chemical and physical data
Formula	C19H18F3N3O2
Molar mass	377.367 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CN1CCC(CC1)C(=O)C2=NC(=CC=C2)NC(=O)C3=C(C=C(C=C3F)F)F;
	InChI InChI=1S/C19H18F3N3O2/c1-25-7-5-11(6-8-25)18(26)15-3-2-4-16(23-15)24-19(27)17-13(21)9-12(20)10-14(17)22/h2-4,9-11H,5-8H2,1H3,(H,23,24,27) ; Key:XEDHVZKDSYZQBF-UHFFFAOYSA-N ;
	(verify)

Lasmiditan, sold under the brand name Reyvow, is a medication used to treat migraines. It is not useful for prevention. The drug is taken by mouth.

Common side effects include sleepiness, dizziness, tiredness, and numbness.

Lasmiditan was approved in the United States in October 2019 and became available in February 2020. It was developed by Eli Lilly. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication. Lasmiditan is a Schedule V controlled substance in the United States.